PATENT

UTILITY PATENT APPLICATION TRANSMITTAL

(only for new non-provisional applications under 37 CFR §1.53(b))

Mail Stop Patent Application Commissioner of Patents P. O. Box 1450 I hereby certify that this correspondence is being deposited with the United States Postal Service as Express Mail in an envelope addressed to Mail Stop Patent Application, Commissioner of Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on Alexandria, VA 22313-1450 Sir: Transmitted herewith for filing is the patent application under 37 CFR 1.53(b) of: Signature EL 964822281 US Express Mail No.

AVENTIS DOCKET NO.: DEAV2002/0095 US CNT INVENTORS: KLEEMANN, et al.

TITLE: 3-Guanidinocarbonyl-1-heteroaryl-indole Derivatives, Preparation process, Their Use as **Medicaments, and Pharmaceutical Compositions Comprising Them**

APPLICATION ELEMENTS

1.	\boxtimes	*Fee Transmittal Form (e.g., PTO/SB/17) (Submit an original and a duplicate for fee processing)								
2.		Specification (preferred arrangement set forth below) - Descriptive title of the Invention - Cross References to Related Applications - Statement Regarding Fed sponsored R & D - Reference to Microfiche Appendix - Background of the Invention - Brief Summary of the Invention - Brief Description of the Drawings (if filed) - Detailed Description - Claim(s) - Abstract of the Disclosure	Total Pages	72						
3.		Drawing(s) (35 U.S.C. 113)	Total Sheets							
4.	Oath a.	or Declaration Newly unexecuted (original or copy)	Total Pages	2						
	b.	Copy from a prior application (37 CFR § 1.	63(d))							
		i. DELETION OF INVENTOR(S) Signed statement attached deleting i application, see 37 CFR §§ 1.63(d)(2)		ed in the prior						
5.	Powe	er of Attorney Newly executed (original or copy)	Total Pages							
	b.	Copy from a prior application (37 CFR § 1.63(d))								
6.		Microfiche Computer Program (Appendix)								

Page 2 7. Nucleotide and/or Amino Acid Sequence Submission (if applicable, all necessary) Computer Readable Copy Paper Copy (identical to computer copy) b. Statement verifying identity of above copies C. If a CONTINUING Application, check appropriate box, and supply the requisite information: Continuation Divisional Continuation-in-part of prior application no: PCT/EP03/07024, filed JULY 2, 2003 Examiner _____, Group/Art Unit _____. This application claims priority to French Application No. FR0208949. filed July 16, 2002. Incorporation By Reference (useable if filing a continuation/divisional and a copy of the declaration from the prio application is enclosed.) The entire disclosure of the prior application, from which a copy of the oath or declaration is supplied, is considered as being part of the disclosure of the accompanying application and is hereby incorporated by reference therein. **ACCOMPANYING APPLICATION PARTS** 7. Assignment Papers (cover sheet & document(s)) 8. 37 CFR §3.73(b) Statement (when there is an assignee) 9. Verified English Translation Document (if applicable) 10. Information Disclosure Copies of IDS Citations Statement (IDS)/PTO-1449 11. Preliminary Amendment 12. Return Receipt Postcard (MPEP 503) (Should be specifically itemized) *Small Entity Statement(s) 13. Statement filed in prior application, (PTO/SB/09-12) Status still proper and desired Certified Copy of Priority Document 14. (if foreign priority is claimed) Other: **Application Data Sheet CORRESPONDENCE ADDRESS** Customer Number or Bar Code Label 005487 (Insert Customer No. or Attach bar code label here) Paul R. Darkes, Reg. No. 33,862 Attorney/Agent for Applicant

Aventis Pharmaceuticals Inc.
Patent Department
Route #202-206 / P.O. Box 6800
Bridgewater, New Jersey 08807-0800
Telephone (908) 231-3638
Telefax (908) 231-2626
Aventis Docket No. DEAV2002/0095 US CNT

Application Transmittal Letter

Approved for use through 04/30/2003. OMB 0651-0032
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number

Complete if Known FEE TRANSMITTAL Application Number Not Yet Assigned Filing Date December 31, 2003 for FY 2004 KLEEMANN, et al. First Named Inventor Patent fees are subject to annual revision. **Examiner Name** Applicant claims small entity status. See 37 CFR 1.27 Group / Art Unit TOTAL AMOUNT OF PAYMENT (\$) 1,292.00 Attorney Docket No. **DEAV2002/0095 US CNT**

METHOD OF PAYMENT (check all that apply)					FEE CALCULATION (continued)						
Check Credit Card Money Other None						3. ADDITIONAL FEES					
Order Deposit Account					Large Entity		Small Entity				
Deposit					Fee	Fee	Fee	Fee			
Number	nber 18-1782			Code	(\$)	Code	(\$)	Fee Description	Fee Paid		
Deposit Account	count Aventis Pharmaceuticals Inc.								•		
Name The Commissioner is authorized to: (check all that apply)						130	2051	65	Surcharge - late filing fee or oath Surcharge - late provisional filing fee or		
Charge fee(s) indicated below Credit any overpayments						50	2052	25	cover sheet		
Charge any additional fee(s) during the pendency of this application						130 2,520	1053 1812	130 2,520	Non-English Specification For filing a request for reexamination		
Charge fee(s) indicated below, except for the filing fee						920*	1804	920*	Requesting publication of SIR prior to		
to the above-identified deposit account FEE CALCULATION						1,840*	1805	1,840*	Examiner action Requesting publication of SIR after		
		TION		1805	·			Examiner action			
1. BASIC FILING FEE					1251	110	2251	55	Extension for reply within first month		
Large Entity Fee Fee Code (\$)			escription	Fee Paid	1252	420	2252	205	Extension for reply within second month		
1001 770			filing fee	770	1253	950	2253	465	Extension for reply within third month		
1002 340		_	n filing Fee		1254	1,480	2254	725	Extension for reply within fourth month		
1003 530	f		filing fee		1255	2,010	2255	985	Extension for reply within fifth month		
1004 770 1005 160			ue filing fee		_1401	330	2401	160	Notice of Appeal		
1005 160	2005		sional filing fee		1402	330	2402	160	Filing a brief in support of an appeal		
		OTAL (1)	(\$)770.00		1403	290	2403	140	Request for oral hearing		
2. EXTRA CLAIM FEES FOR UTILITY AND REISSUE					1451	1,510	1451	1,510	Petition to institute a public use proceeding		
		Extra	Fee from	- Fee	1452	110	2452	55	Petition to revive - unavoidable		
		Claims	below	Paid	·						
	-20		x 18	= 522	1453	1,330	2453	650	Petition to revive - unintentional		
Independent	- 3	*= 0	x 0	= 0	1501	1,330	2501	650	Utility issue fee (or reissue)		
Claims					1502 1503	480 640	2502 2503	235 315	Design issue fee Plant issue fee		
Multiple Dependent 0 = 0					1460	130	1460	130	Petitions to the Commissioner		
Large Entity Small Entity						50	1807	50	Petitions related to provisional		
Fee Fee Code (\$)		Fee (\$) Fee D	escription						applications		
1202 18	2202	•••	s in excess of 20)	1806	180	1806	180	Submission of Information Disclosure Stmt		
1201 86	2201	42 Indep	Independent claims in excess of 3			40	8021	40	Recording each patent assignment per property (times number of properties)		
1203 290	2203	140 Multip paid	Multiple dependent claim, if not paid			770	2809	375	Filing a submission after final rejection (37 CFR § 1.129(a))		
1204 86	2204		**Reissue independent claims over original patent			770	2810	375	For each additional invention to be examined (37 CFR § 1.129(b))		
1205 18 2205 9 **Reissue claims in excess of 20 and over original patent			1801	770	2801	375	Request for Continued Examination (RCE)				
			<u> </u>		1802	900	1802	900	Request for expedited examination of a design application		
SUBTOTAL (2) (\$)522.00					Other fee	Other fee (specify)			***************************************		
**or number previously paid, if greater; For Reissues, see above				*Reduced by Basic Filing Fee Paid			Paid	SUBTOTAL (3) (\$)			

SUBMITTED BY		Complete (If applie			oplicable)			
Name (Print/Type)	Paul R. Darkes, Reg. No. 33/862	I_{I}	า	Registration No. (Attorney/Agent)	33,862	Telephone	(908) 231-3638	
Signature	Level Milen	U	1			Date	31 Dec 200	53

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

This collection of information is required by 37 CFR 1.17 and 1.27. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Office, U.S. Patent and Trademark Office, Alexandria, VA 22313. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P. O. Box 1450, Alexandria,